

CLAIMS

1. Use of an antibody that neutralizes the inhibitory activity of human NKG2A in the preparation of a medicament for the treatment of non-small cell lung cancer in a human patient, in which an effective amount of each of: (a) an antibody that neutralizes the inhibitory activity of human NKG2A, and (b) an antibody that neutralizes the inhibitory activity of human PD-1 are to be administered to the patient.
2. Use according to Claim 1, in which the antibody that neutralizes the inhibitory activity of human NKG2A comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in any one of SEQ ID NOS: 4-8, and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 9.
3. Use according to Claim 1 or 2, in which the antibody that neutralizes the inhibitory activity of human NKG2A comprises the CDR1, CDR2 and CDR3 domains of a heavy chain having the sequence set forth in SEQ ID NO: 5 and the CDR1, CDR2 and CDR3 domains of a light chain having the sequence set forth in SEQ ID NO: 9.
4. Use according to Claim 1, 2 or 3, in which the antibody that neutralizes the inhibitory activity of human NKG2A comprises a heavy chain having the sequence set forth in SEQ ID NO: 5 and a light chain having the sequence set forth in SEQ ID NO: 9.
5. Use according to any preceding claim, in which the antibody that neutralizes the inhibitory activity of human PD-1 is selected from the group consisting of pembrolizumab, nivolumab, AMP-514, MEDI-4736, CT-011 and MPDL3280A.
6. Use according to any preceding claim, in which the antibody that neutralizes the inhibitory activity of human PD-1 is MEDI-4736.
7. Use according to any of Claims 1 to 4, in which the antibody that neutralizes the inhibitory activity of human PD-1 is an anti-PD-L1 antibody that inhibits the binding of PD-L1 to PD-1.
8. Use according to Claim 7, in which the anti-PD-L1 antibody is MEDI-4736.
9. Use according to any preceding claim, in which at least two doses of the antibody that neutralizes the inhibitory activity of human NKG2A are to be administered in an amount

effective to achieve a continuous blood concentration of anti-NKG2A antibody of at least 10 µg/ml for at least one week following administration thereof.

10. Use according to any preceding claim, in which the treatment comprises at least one administration cycle, in which for each cycle, two, three or four doses of the antibody that neutralizes the inhibitory activity of human NKG2A are to be administered and two, three or four doses of the antibody that neutralizes the inhibitory activity of PD-1 antibody are to be administered.
11. Use according to any preceding claim, in which the antibody that neutralizes the inhibitory activity of human NKG2A and the antibody that neutralizes the inhibitory activity of PD-1 are formulated for separate administration and are to be administered concurrently or sequentially.
12. Use according to any of Claims 1 to 10, in which the antibody that neutralizes the inhibitory activity of human NKG2A and the antibody that neutralizes the inhibitory activity of PD-1 are to be administered in a single formulation.
13. Use according to any preceding claim, in which the antibody that neutralizes the inhibitory activity of human NKG2A and the antibody that neutralizes the inhibitory activity of PD-1 are to be administered on the same day.
14. Use according to any preceding claim, in which the non-small cell lung cancer is an HLA-E-expressing cancer.
15. Use according to any preceding claim, in which the non-small cell lung cancer is an advanced cancer.
16. Use according to any preceding claim, in which the non-small cell lung cancer is a refractory cancer.
17. Use according to any preceding claim, in which the antibody that neutralizes the inhibitory activity of NKG2A is a non-depleting antibody.
18. Use according to any preceding claim, in which the antibody that neutralizes the inhibitory activity of NKG2A is an IgG4 antibody, in which the antibody that neutralizes the inhibitory activity of human NKG2A lacks an Fc domain or in which the antibody that

neutralizes the inhibitory activity of human NKG2A comprises an Fc domain that is modified to reduce binding between the Fc domain and an Fcγ receptor.

19. Use according to Claim 10, in which the at least one administration cycle comprises a period of eight weeks.

- 5 20. Use of an antibody that neutralizes the inhibitory activity of human NKG2A in the preparation of a medicament for the treatment of non-small cell lung cancer in a human patient, in which an effective amount of each of: (a) an antibody that neutralizes the inhibitory activity of human NKG2A comprising a heavy chain having the sequence set forth in SEQ ID NO: 5 and a light chain having the sequence set forth in SEQ ID NO: 9, and (b) an antibody
10 that neutralizes the inhibitory activity of human PD-1, in which the antibody that neutralizes the inhibitory activity of human PD-1 is MEDI-4736, are to be administered to the patient.